A controversial anti-mitotic treatment using electric fields to disrupt glioblastoma cell division has been shown to improve survival in an open label, phase 3 trial. The study, published in JAMA, comprised 695 patients with glioblastoma following resection and initial radiochemotherapy. Patients were randomised to either maintenance temozolomide alone or in combination with low dose, alternating ...
Head and Neck Cancer
Scepticism over electric field therapy for glioblastoma
By Mardi Chapman
19 Jan 2018